AstraZeneca said on Thursday its nerve disease drug Wainua, made in partnership with US-based Ionis, failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.The trial was for patients with a type of heart disease that lets protein build up in the heart, disrupting blood pumping and possibly causing heart failure. Adding Wainua to standard care did not provide a statistically significant benefit, the trial found.Wainua is approved in more than 20 countries to treat patients with polyneuropathy, a life-shortening rare disease that causes nerve damage.In the late-stage trial, Wainua was being tested in 1,432 patients compared to placebo over 140 weeks.Published on July 9, 2026